<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00403689</url>
  </required_header>
  <id_info>
    <org_study_id>MOW_bGlucan</org_study_id>
    <nct_id>NCT00403689</nct_id>
  </id_info>
  <brief_title>Effects of (1,3), (1,6)-Beta-D-glucan on Insulin Sensitivity and Inflammatory Markers of the Metabolic Syndrome</brief_title>
  <official_title>Effects of (1,3), (1,6)-Beta-D-glucan on Insulin Sensitivity and Inflammatory Markers of the Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Institute of Human Nutrition</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danone Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiber Company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>German Institute of Human Nutrition</source>
  <brief_summary>
    <textblock>
      Insoluble (1,3),(1,6)-beta-D-glucan from bakers yeast are indigestible polysaccharides.
      Previous studies indicate that the intake of insoluble dietary fiber is strongly associated
      with reduced risk of type 2 diabetes and cardiovascular disease. However, the mechanisms
      leading to this phenomenon are largely unknown.

      There are close relations between metabolic and inflammatory pathways, and a number of
      hormones, cytokines, signal proteins, bioactive lipids, and transcription factors have been
      shown to be involved in both systems.

      Beta-D-glucans have been suggested to play a role as so called biological response modifiers.
      Studies in animals indicate that even small doses of (1,3),(1,6)-beta-D-glucan may have
      beneficial effects on immune activity, i.e., by reducing the secretion of inflammatory
      factors.

      The investigators hypothesize that the intake of isolated (1,3), (1,6)-beta-D-glucan from
      bakers yeast improves inflammatory makers and insulin-sensitivity in overweight subjects with
      increased C-reactive protein concentrations at baseline.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Beta-D-glucan induced changes in inflammatory markers, adipokines, and gut hormones. Changes in insulin-sensitivity.</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Altered gene expression in adipose tissue if changes in primary outcome measures are shown.</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>x</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capsules containing beta glycan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>y</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>capsules containing placebo (waxy maize starch)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Beta-D-Glucan</intervention_name>
    <description>1,5 g Beta-D-Glucan daily</description>
    <arm_group_label>x</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>1.5 g waxy maize starch daily</description>
    <arm_group_label>y</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects with normal glucose tolerance (NGT)

          -  Impaired glucose tolerance (IGT)

          -  Impaired fasting glucose (IFG)

        Exclusion Criteria:

          -  Any severe cardiac disease

          -  Liver

          -  Kidney diseases

          -  Type 1 or type 2 diabetes

          -  Chronical and acute inflammatory diseases

          -  Lipid lowering drugs

          -  Cortisone

          -  Antibiotics

          -  Non-steroidal antiinflammatory drugs

          -  Including low dose acetylsalicylic acid
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin O Weickert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>German Institute of Human Nutrition</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas FH Pfeiffer, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>German Institute of Human Nutrition</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>German Institute of Human Nutrition, Department of Clinical Nutrition, Potsdam-Rehbrücke</name>
      <address>
        <city>Nuthetal</city>
        <zip>14558</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.dife.de</url>
  </link>
  <results_reference>
    <citation>Kohl A, Gögebakan O, Möhlig M, Osterhoff M, Isken F, Pfeiffer AF, Weickert MO. Increased interleukin-10 but unchanged insulin sensitivity after 4 weeks of (1, 3)(1, 6)-beta-glycan consumption in overweight humans. Nutr Res. 2009 Apr;29(4):248-54. doi: 10.1016/j.nutres.2009.03.002.</citation>
    <PMID>19410976</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2006</study_first_submitted>
  <study_first_submitted_qc>November 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2006</study_first_posted>
  <last_update_submitted>August 1, 2013</last_update_submitted>
  <last_update_submitted_qc>August 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>German Institute of Human Nutrition</investigator_affiliation>
    <investigator_full_name>Weickert, Martin O.</investigator_full_name>
    <investigator_title>Chief Investigator</investigator_title>
  </responsible_party>
  <keyword>Increased non-specific inflammatory markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

